Quark Pharmaceuticals Quark Pharmaceuticals
  • About Us
    • About Us
    • Executive Management
      • Senior Management
      • RiboQuark Joint Venture
    • Quark Timeline
  • Pipeline
    • Pipeline
    • QPI-1002
    • QPI-1007
    • PF-655
    • Preclinical Indications
  • Technology
    • Technology
    • Publications
  • Partners
    • Partners
    • Scientific Collaborations
  • Intellectual Property
    • Intellectual Property
    • IP Announcements
  • News
    • News
    • Events
  • Contact
    • Contact
    • Careers

IP Announcements

­
IP Announcementseyal2015-12-09T14:28:39+00:00
eyal2015-12-09T13:46:51+00:00

Quark announces issue of U.S. patent for novel treatment of lung transplantation associated injury

December 9th, 2015

eyal2015-09-02T11:11:14+00:00

Quark announces patent approval for Methods for treating eye disorders

September 1st, 2015

eyal2015-09-02T10:35:47+00:00

Quark announces patent approval for Compositions and methods for treatment of ear disorders

July 28th, 2015

eyal2015-09-02T10:35:59+00:00

Quark announces patent approval for therapeutic uses of inhibitors of RTP801

June 16th, 2015

eyal2015-09-02T10:36:12+00:00

Quark announces patent approval for double stranded RNA compounds to RhoA and use thereof

June 2nd, 2015

eyal2015-09-02T11:17:56+00:00

Quark announces patent approval for oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases

April 14th, 2015

eyal2015-09-02T10:29:03+00:00

Quark announces patent approval for Methods for delivery of siRNA to the spinal cord and therapies arising therefrom

December 2nd, 2014

eyal2015-09-02T10:30:32+00:00

Quark announces Patent Approval for Oligonucleotide compounds comprising non-nucleotide overhangs

October 14th, 2014

eyal2015-09-02T10:31:51+00:00

Quark announces patent approval for Sirna compounds comprising terminal substitutions

August 5th, 2014

  • Intellectual Property
  • IP Announcements

About Quark

Quark Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is a leader in the discovery and development of novel RNAi-based therapeutics.

Contact Info

Headquarters

Quark Pharmaceuticals, Inc. USA
6501 Dumbarton Circle
Fremont, CA 94555
Phone: 510.402.4020
Fax: 510.402.4021
Email: qbi@quarkpharma.com

Research

QBI Enterprises, Ltd.
Weizmann Science Park, P.O.B. 4071
Ness Ziona, 70400, Israel.
Phone: 972-8-9305-111
Fax: 972-8-9406-476
E-mail: qbi@quarkpharma.com

Human Resource

For US operations: HR_US@quarkpharma.com
For Israel operations: HR_IL@quarkpharma.com

Business Development

Juliana Friedman
Email: JFriedman@quarkpharma.com

Categories

  • Events
  • News
  • Open Positions In Israel
  • Patents

Terms Of Use

  • Terms of Use
  • Copyright Info
  • Privacy Policy
Copyright 2015 Quark | All Rights Reserved